U.S. Markets close in 4 hrs 22 mins

Intec Pharma Ltd (NTEC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.7700+0.1400 (+3.86%)
As of 11:38AM EDT. Market open.

Intec Pharma Ltd

RMPE building
12 Hartom Street Har Hotzvim PO Box 45219
Jerusalem 9777512
Israel
972 2 586 4657
http://www.intecpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees36

Key Executives

NameTitlePayExercisedYear Born
Mr. Jeffrey A. MecklerVice Chairman & CEO798.12kN/A1967
Mr. Nir SassiCFO & Pres378.47kN/A1976
Dr. Nadav Navon Ph.D.Chief Operating Officer410.63kN/A1969
Mr. Walt Addison LinscottChief Bus. Officer557.93kN/A1961
Anne Marie FieldsVP of Corp. Communications & Investor RelationsN/AN/AN/A
Mr. Zeev Weiss B.Sc., C.P.A.Clinical & Bus. Devel. ConsultantN/AN/A1962
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Intec Pharma Ltd, a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which has completed a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various pain indications. Intec Pharma Ltd. has a research collaboration agreement with Merck Sharp & Dohme for the development of Accordion Pill; and a cannabinoid research collaboration agreement with GW Research Limited to explore an undisclosed research program using the Accordion Pill platform. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd in March 2004. Intec Pharma Ltd was incorporated in 2000 and is based in Jerusalem, Israel.

Corporate Governance

Intec Pharma Ltd’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.